Cstone/EQRX and Shanghai Junshi/Coherus might have approvable anti-PD-(L)1 projects, but can Keytruda be challenged on price?
At a conference largely focused on big biopharma a few biotech catalysts stand out.
The first of 2021’s eight remaining oncology meetings kicks off next week. Here’s what to look out for.
Spac redemptions are a growing concern, but the $1.8bn EQRX deal looks primed to succeed. Proving the business model will be the hard part.
Promises to act on pharma’s financial toxicity increasingly seem to lack bite, but EQRX promises to follow its words with real action.
Like Aduhelm this long-discontinued amyloid beta MAb reduced brain beta amyloid; so have several other industry projects.
The long overdue advent of US cut-price oncology drugs is a major theme at this year’s Asco, and Junshi’s toripalimab leads the way.
With a record $7.1bn raised in the first quarter the cash available to private drug developers shows no signs of drying up.